ARTICLE | Product Development
Evelo to advance microbiome modality to registrational study
Phase II data raise questions about efficacy while pointing to safety advantage in mild-to-moderate psoriasis
September 28, 2021 1:12 AM UTC
Evelo is moving forward with plans to bring microbiome therapy EDP1815 into registrational studies for psoriasis, but the Phase II data supporting that decision raise questions about how effective a highly tolerable therapy needs to be, and which endpoints can best assess efficacy in patients with mild-to-moderate disease.
Evelo Biosciences Inc. (NASDAQ:EVLO) announced positive results from the study in 249 patients with mild to moderate psoriasis. Investors pushed Evelo’s shares down 15% in early trading; however, the stock ended Monday up $0.17 at $7.42...